Maze Therapeutics, Inc.
Maze Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Assets Current | |||||||||||
Cash And Cash Equivalents At Carrying Value | 203 | 199 | 189 | 317 | 265 | 294 | |||||
Marketable Securities Current | 208 | 154 | 153 | 67 | - | - | |||||
Accounts Receivable Net Current | - | 20 | - | - | - | - | |||||
Prepaid Expense And Other Assets Current | 9 | 7 | 8 | 7 | 7 | 5 | |||||
Assets Current | 420 | 380 | 350 | 391 | 271 | 300 | |||||
Property Plant And Equipment Net | 4 | 5 | 5 | 6 | 6 | 6 | |||||
Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Marketable Securities Noncurrent | 84 | 11 | 18 | - | - | - | |||||
Operating Lease Right Of Use Asset | 18 | 19 | 20 | 21 | 22 | 22 | |||||
Other Assets Noncurrent | 3 | 4 | 3 | 3 | 4 | 3 | |||||
Assets | 532 | 420 | 397 | 422 | 304 | 333 | |||||
Liabilities And Stockhold… | |||||||||||
Liabilities Current | |||||||||||
Accounts Payable Current | 2 | 4 | 2 | 3 | 4 | 2 | |||||
Accrued Liabilities And Other Liabilities | 16 | 12 | 16 | 14 | 12 | 12 | |||||
Operating Lease Liability Current | 5 | 5 | 5 | 5 | 5 | 5 | |||||
Liabilities Current | 23 | 21 | 23 | 22 | 20 | 19 | |||||
Operating Lease Liability Noncurrent | 17 | 18 | 19 | 19 | 20 | 21 | |||||
Long Term Debt Noncurrent | 39 | 39 | - | - | - | - | |||||
Other Liabilities Noncurrent | - | 0 | 1 | 1 | 1 | 1 | |||||
Liabilities | 79 | 78 | 42 | 43 | 41 | 41 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | - | 0 | - | - | - | |||||
Stockholders Equity | |||||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 1,012 | 856 | 844 | 834 | 687 | 683 | |||||
Accumulated Other Comprehensive Income Loss Availa… | -0 | -0 | 0 | 0 | - | - | |||||
Retained Earnings Accumulated Deficit | -558 | -514 | -490 | -455 | -425 | -391 | |||||
Stockholders Equity | 453 | 342 | 355 | 379 | 262 | 292 | |||||
Liabilities And Stockholders Equity | 532 | 420 | 397 | 422 | 304 | 333 | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | 0.001 | |||||
Redeemable Convertible Preferred Stock | - | - | 0 | 0 | -33 | 33 | |||||
Preferred Stock | - | 0 | 0 | -0 | -33 | 33 | |||||
Preferred Stock Shares Authorized | - | - | - | - | - | 10 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | |||||
Common Stock Shares Issued | 56 | 50 | 49 | 48 | 44 | 44 | |||||
Shares Outstanding | 56 | 50 | 49 | 48 | 44 | 44 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.86% | 21.26% | 7.18% | - | - | - | - | - | - | - | - | - |
| 2025 | 42.72% | 26.93% | 64.46% | 15.57% | 97.31% | 139.52% | 27.40% | 42.09% | 49.41% | -11.47% | -19.45% | -24.20% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Maze Therapeutics, Inc. (MAZE) — SEC Financial Statements & Analysis
Maze Therapeutics, Inc. (MAZE) is a biological products, (no diagnostic substances) company, incorporated in DE. Maze Therapeutics, Inc. trades on Nasdaq as: MAZE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Maze Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.17x, a Price-to-Sales (P/S) ratio of 88.02x (TTM), a Price-to-Book (P/B) ratio of 3.89x (TTM), at a market cap of $1.76B. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.17x
- P/S TTM
- 88.02x
- P/B TTM
- 3.89x
- Market Cap
- $1.76B
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Maze Therapeutics, Inc. in?
Maze Therapeutics, Inc. (MAZE) operates in the Biological Products, (No Diagnostic Substances) industry.
What is MAZE's market cap?
Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.76B as of 2026-06-30.
What exchange does MAZE trade on?
Maze Therapeutics, Inc. (MAZE) trades on the Nasdaq.
Where is Maze Therapeutics, Inc. incorporated?
Maze Therapeutics, Inc. is incorporated in DE.